IDEAYA Biosciences recently reported first-patient-in for a global Phase 1 trial combining IDE849, a DLL3-targeting Topo-I ADC, with IDE161, a PARG inhibitor, in DLL3-upregulated solid tumors such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results